Chronic Lymphocytic Leukemia

Real-world data suggest optimal CLL/SLL treatment sequencing involves targeted therapies, including covalent BTKis and BCL2 inhibitors, for better survival outcomes.

Pirtobrutinib, venetoclax, and obinutuzumab demonstrated a numerically higher rate of undetectable minimal residual disease vs ibrutinib and venetoclax in chronic lymphocytic leukemia.

The novel Bruton tyrosine kinase degrader BGB-16673 shows promise in relapsed/refractory Waldenström macroglobulinemia previously exposed to BTK inhibitors, and in heavily pretreated patients with R/R chronic lymphocytic leukemia/small lymphocytic lymphoma.

Pirtobrutinib, a third-generation BTK inhibitor, showed superior progression-free survival and lower treatment discontinuation rates vs investigator's choice in previously treated CLL/SLL.

Initial therapy with sonrotoclax and zanubrutinib showed strong efficacy and acceptable safety in untreated CLL/SLL.

The bispecific T-cell engager epcoritamab demonstrated favorable efficacy outcomes with manageable toxicities in patients treated in the expansion and optimization cohorts of the EPCORE CLL-1 trial.

Susan L. Slager, PhD, discusses some of the recommendations for genetic testing in individuals with a family history of chronic lymphocytic leukemia.

Susan L. Slager, PhD, discusses the use of polygenic risk scoring to assess individual risk for CLL.

Susan L. Slager, PhD, discusses the background of her research on inherited germline genetics for risk of chronic lymphocytic leukemia.

The FDA updated the fludarabine phosphate injection labeling under Project Renewal, clarifying the dosage for combination therapy and streamlining safety warnings.

Nicole Lamanna, MD, discussed some of the ongoing clinical trials evaluating new therapies for patients with chronic lymphocytic leukemia.

Cyrus M. Khan, MD, discussed recent advancements in CLL treatment, particularly the shift to nonchemotherapy options and the availability of CAR T-cell therapy.

Alessandra Ferrajoli, MD, discusses the importance of supportive care in the management of patients with chronic lymphocytic leukemia with comorbidities.

Susan L. Slager, PhD, discussed the etiology and inherited genetic factors that are associated with the risk of chronic lymphocytic leukemia.

John Seymour, MD, discusses the development and clinical application of BCL-2 inhibitors for the treatment of CLL.

Cyrus M. Khan, MD, highlights some of the most recent and significant advancements in chronic lymphocytic leukemia treatment.

During a Case-Based Roundtable® event, Andrew H. Lipsky, MD, moderated a discussion on the efficacy and safety of newer BTK inhibitors used to treat patients with chronic lymphocytic leukemia.

Debaters Andres Chang, MD, PhD, and Jean Louise Koff, MD, MS, led the verbal battle at the Debates and Didactics in Hematology and Oncology Conference held from July 25 to 28, 2024, in Sea Island, Georgia.

The decision to discontinue BTK inhibitor treatment for CLL is complex, with emerging data suggesting that time-limited therapy may be feasible in certain cases, particularly when combined with other targeted agents.

Combination therapies in CLL are generating excitement with ongoing trials that could expand standard practice for the future.

Alessandra Ferrajoli, MD, discusses the comorbidities that can impact the management of patients with chronic lymphocytic leukemia and some of the available treatment options in this space.

Alessandra Ferrajoli, MD, discusses the session she was a part of at the 2024 Society of Hematologic Oncology Annual Meeting.

Findings from a real-world study showed that zanubrutinib was associated with lower rates of treatment switching and patients receiving subsequent therapy compared with acalabrutinib and ibrutinib in patients with CLL or SLL.

Response outcomes with liso-cel were consistent regardless of the presence of high-risk disease features in patients with relapsed/refractory chronic lymphocytic leukemia.

Jeff Sharman, MD, discusses the clinical implications for oncologists based on data from the ELEVATE-TN trial.